Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Adams

Showing results (201-210 of 291) with videos related to

Pageof 30
Sort By:
BMJ Open Diabetes Research & Care|April 27, 2025
Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT studyMuhammad Abdul-Ghani, Curtiss Puckett, Siham Abdelgani, et al.
Frontiers in Health Services|February 5, 2025
Measuring how healthcare organizations respond after patients experience harm: perspectives and next stepsLauge Sokol-Hessner, John Adams, Carole Hemmelgarn, et al.
Brain : a Journal of Neurology|December 15, 2006
Amygdala dysfunction in men with the fragile X premutationDavid Hessl, Susan Rivera, Kami Koldewyn, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|August 29, 2023
Generalized Dystonia With Tremor and Myoclonus Associated With ANO3 VariantDaniel G Di Luca, Talyta C Grippe, John Adams, et al.
Diabetes Care|June 16, 2017
Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325-331Muhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
Diabetes Care|December 4, 2020
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICTMuhammad Abdul-Ghani, Curtiss Puckett, John Adams, et al.
Molecules (Basel, Switzerland)|January 21, 2023
Advances in the Chemistry, Analysis and Adulteration of Anthocyanin Rich-Berries and Fruits: 2000-2022Bharathi Avula, Kumar Katragunta, Ahmed G Osman, et al.
Health Services Research|April 5, 2011
Cost implications to health care payers of improving glucose management among adults with type 2 diabetesTeryl K Nuckols, Elizabeth A McGlynn, John Adams, et al.
Diabetes Care|January 19, 2017
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar StudyMuhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 16, 2019
The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental ColitisHussien Al-Shamma, Karin Lehmann-Bruinsma, Chris Carroll, et al.
Pageof 30

Showing results (201-210 of 291) with videos related to

Sort By:
Pageof 30
BMJ Open Diabetes Research & Care|April 27, 2025
Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT studyMuhammad Abdul-Ghani, Curtiss Puckett, Siham Abdelgani, et al.
Frontiers in Health Services|February 5, 2025
Measuring how healthcare organizations respond after patients experience harm: perspectives and next stepsLauge Sokol-Hessner, John Adams, Carole Hemmelgarn, et al.
Brain : a Journal of Neurology|December 15, 2006
Amygdala dysfunction in men with the fragile X premutationDavid Hessl, Susan Rivera, Kami Koldewyn, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|August 29, 2023
Generalized Dystonia With Tremor and Myoclonus Associated With ANO3 VariantDaniel G Di Luca, Talyta C Grippe, John Adams, et al.
Diabetes Care|June 16, 2017
Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325-331Muhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
Diabetes Care|December 4, 2020
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICTMuhammad Abdul-Ghani, Curtiss Puckett, John Adams, et al.
Molecules (Basel, Switzerland)|January 21, 2023
Advances in the Chemistry, Analysis and Adulteration of Anthocyanin Rich-Berries and Fruits: 2000-2022Bharathi Avula, Kumar Katragunta, Ahmed G Osman, et al.
Health Services Research|April 5, 2011
Cost implications to health care payers of improving glucose management among adults with type 2 diabetesTeryl K Nuckols, Elizabeth A McGlynn, John Adams, et al.
Diabetes Care|January 19, 2017
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar StudyMuhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 16, 2019
The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental ColitisHussien Al-Shamma, Karin Lehmann-Bruinsma, Chris Carroll, et al.
Pageof 30